This site is intended for health professionals only
Wednesday 20 March 2019
Share |

Takeda to market the CALCICHEW® portfolio in the UK and Ireland

Takeda UK Limited has announced that it is now the sole holder of the Marketing Authorisation for the CALCICHEW® portfolio in UK and Ireland following a transfer from Shire Pharmaceuticals Ireland Limited.
Vitamin D

 

Takeda UK Limited has announced that it is now the sole holder of the Marketing Authorisation for the CALCICHEW® portfolio in UK and Ireland following a transfer from Shire Pharmaceuticals Ireland Limited.

 

Takeda will be responsible for the promotion, marketing, sales and distribution of the CALCICHEW® portfolio in both countries.  The financial arrangements related to this agreement have not been disclosed and remain confidential between Takeda and Shire. 

 

“The transfer of Marketing Authorisation for the CALCICHEW® portfolio is a great development for Takeda and it will add significant financial revenues to Takeda in the UK and Ireland and there is significant potential for growth in both countries” said Yasuhiro Fukutomi, Managing Director, Takeda UK and Cluster Lead for UK & Ireland.  He continues “we are also very pleased to be able to continue to work in the area of osteoporosis, offering patients and physicians treatment choice and support to help with the management of this disease”.

 

The CALCICHEW D3 portfolio is indicated for the prevention and treatment of vitamin D/calcium deficiency and for the supplementation of vitamin D and calcium as an adjunct to specific therapy for osteoporosis, in pregnancy, in established vitamin D dependent osteomalacia and in other situations requiring therapeutic supplementation of malnutrition.(1) It consists of a number of products containing calcium, with or without vitamin D3.  The major patient group, which is prescribed calcium and/or vitamin D3, is the elderly (especially women) who are at risk of or have diagnosed osteoporosis and/or have an increased risk of falls.

 

The supply and distribution of CALCICHEW® products will not be affected by the marketing authorisation transfer. CALCICHEW® products can be ordered as before using PIP/EAN codes as these will not be affected by the transfer. Questions relating to the supply of the CALCICHEW® portfolio can be directed to Takeda UK Medical Information on DSO-UK@takeda.com / 01628 537 900. 

 

Reference

  1. CALCICHEW D3 Forte Tablets. Summary of product characteristics (SmPC). Available at http://www.medicines.org.uk/emc/. Last accessed November 2013

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine